MiRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma

Jisce R. Puik; Laura L. Meijer; Tessa Y.S. Le Large; Mireia Mato Prado; Adam E. Frampton; Geert Kazemier; Elisa Giovannetti

doi:https://doi.org/10.2217/pgs-2017-0010

MiRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma

Jisce R. Puik, Laura L. Meijer, Tessa Y.S. Le Large, Mireia Mato Prado, Adam E. Frampton, Geert Kazemier, Elisa Giovannetti

Research output: Contribution to journal › Review article › Academic › peer-review

41 Citations (Scopus)

Abstract

Cholangiocarcinoma (CCA) is a lethal malignancy originating from the biliary tract epithelium. Most patients are diagnosed at an advanced stage. Even after resection with curative intent, prognosis remains poor. Previous studies have reported the evolving role of miRNAs as novel biomarkers in cancer diagnosis, prognostication and chemotherapy response. Various miRNAs, such as miR-21, miR-26, miR-122 and miR-150, have been identified as possible blood-based biomarkers for noninvasive diagnosis of CCA. Moreover, epithelial-mesenchymal transition (EMT)- and angiogenesis-associated miRNAs have been implicated in tumor cell dissemination and are able to determine clinical outcome. In fact, miRNAs involved in cell survival might even determine chemotherapy response. This review provides an overview of known miRNAs as CCA-specific biomarkers.

Original language	English
Pages (from-to)	1343-1358
Number of pages	16
Journal	Pharmacogenomics
Volume	18
Issue number	14
Early online date	2017
DOIs	https://doi.org/10.2217/pgs-2017-0010
Publication status	Published - 1 Sept 2017

Keywords

bile duct cancer
cholangiocarcinoma
diagnosis
liquid biopsy
miRNA
prediction
prognosis

Access to Document

https://doi.org/10.2217/pgs-2017-0010

Cite this

@article{4a3c550f5d5648418cad29888e1a2891,

title = "MiRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma",

abstract = "Cholangiocarcinoma (CCA) is a lethal malignancy originating from the biliary tract epithelium. Most patients are diagnosed at an advanced stage. Even after resection with curative intent, prognosis remains poor. Previous studies have reported the evolving role of miRNAs as novel biomarkers in cancer diagnosis, prognostication and chemotherapy response. Various miRNAs, such as miR-21, miR-26, miR-122 and miR-150, have been identified as possible blood-based biomarkers for noninvasive diagnosis of CCA. Moreover, epithelial-mesenchymal transition (EMT)- and angiogenesis-associated miRNAs have been implicated in tumor cell dissemination and are able to determine clinical outcome. In fact, miRNAs involved in cell survival might even determine chemotherapy response. This review provides an overview of known miRNAs as CCA-specific biomarkers.",

keywords = "bile duct cancer, cholangiocarcinoma, diagnosis, liquid biopsy, miRNA, prediction, prognosis",

author = "Puik, {Jisce R.} and Meijer, {Laura L.} and {Le Large}, {Tessa Y.S.} and Prado, {Mireia Mato} and Frampton, {Adam E.} and Geert Kazemier and Elisa Giovannetti",

year = "2017",

month = sep,

day = "1",

doi = "https://doi.org/10.2217/pgs-2017-0010",

language = "English",

volume = "18",

pages = "1343--1358",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine Ltd.",

number = "14",

}

TY - JOUR

T1 - MiRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma

AU - Puik, Jisce R.

AU - Meijer, Laura L.

AU - Le Large, Tessa Y.S.

AU - Prado, Mireia Mato

AU - Frampton, Adam E.

AU - Kazemier, Geert

AU - Giovannetti, Elisa

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Cholangiocarcinoma (CCA) is a lethal malignancy originating from the biliary tract epithelium. Most patients are diagnosed at an advanced stage. Even after resection with curative intent, prognosis remains poor. Previous studies have reported the evolving role of miRNAs as novel biomarkers in cancer diagnosis, prognostication and chemotherapy response. Various miRNAs, such as miR-21, miR-26, miR-122 and miR-150, have been identified as possible blood-based biomarkers for noninvasive diagnosis of CCA. Moreover, epithelial-mesenchymal transition (EMT)- and angiogenesis-associated miRNAs have been implicated in tumor cell dissemination and are able to determine clinical outcome. In fact, miRNAs involved in cell survival might even determine chemotherapy response. This review provides an overview of known miRNAs as CCA-specific biomarkers.

AB - Cholangiocarcinoma (CCA) is a lethal malignancy originating from the biliary tract epithelium. Most patients are diagnosed at an advanced stage. Even after resection with curative intent, prognosis remains poor. Previous studies have reported the evolving role of miRNAs as novel biomarkers in cancer diagnosis, prognostication and chemotherapy response. Various miRNAs, such as miR-21, miR-26, miR-122 and miR-150, have been identified as possible blood-based biomarkers for noninvasive diagnosis of CCA. Moreover, epithelial-mesenchymal transition (EMT)- and angiogenesis-associated miRNAs have been implicated in tumor cell dissemination and are able to determine clinical outcome. In fact, miRNAs involved in cell survival might even determine chemotherapy response. This review provides an overview of known miRNAs as CCA-specific biomarkers.

KW - bile duct cancer

KW - cholangiocarcinoma

KW - diagnosis

KW - liquid biopsy

KW - miRNA

KW - prediction

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=85028834977&partnerID=8YFLogxK

U2 - https://doi.org/10.2217/pgs-2017-0010

DO - https://doi.org/10.2217/pgs-2017-0010

M3 - Review article

C2 - 28832247

SN - 1462-2416

VL - 18

SP - 1343

EP - 1358

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 14

ER -

MiRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma

Abstract

Keywords

Access to Document

Other files and links

Cite this